Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by august202013on Aug 08, 2024 11:08am
124 Views
Post# 36169483

RECOMMENDATION FOR HC HOW TO NAVIGATE MOVING FORWARD

RECOMMENDATION FOR HC HOW TO NAVIGATE MOVING FORWARD Long Term Minority Shareholders should come forward with recommendation for MM on how medmira should navigate moving forward STARTING with if Medmira should just WAIT for HC approval for their SYPHILIS SUBMISSIION/APPLICATION before making "PRESS RELEASE" after 17-7-2024. OR


Make another attempt to produce COLON CANCER TEST KIT as Big Brother just issued last month APPROVAL for a California based company.
Medmira could submit one application for Big Brother and one for HC. And yes one for EUROPE for the CE mark for their approval after successfully completing one SEE any of these 2 entity would issue their approval.
Most likely will delay again until the market is flooded than still processing EUROPE might give their CE mark and with that should proceed to market to Asia as COLON CANCER TEST KIT could be viable if prices RIGHT

<< Previous
Bullboard Posts
Next >>